The release, publication or distribution of this information in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which they are released, published or distributed, should inform themselves about, and observe, such restrictions. The pages contain information relating to an offering by TME PHARMA N.V. that is exempted under the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 and the Dutch Exemption Regulations pursuant to the Dutch Financial Supervision Act (Vrijstellingsregeling Wft) (considering total consideration being less than EUR 5 million).
This information does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United Kingdom, United States, Australia, Canada, or Japan or in any jurisdiction in which such offers or sales are unlawful. Any securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under any applicable securities laws of any state, province, territory, county or jurisdiction of the United Kingdom, United States, Australia, Canada, or Japan.
TME PHARMA LAUNCHES FULLY GUARANTEED PUBLIC OFFER FOR €2.6 MILLION TO ENABLE STRATEGIC TRANSACTIONS AROUND NOX-A12 AND NOX-E36 BY JUNE 2025
The launch of capital increase is carried out through a public offer reserved for the company's shareholders only, determined as at the record date of December 11, 2024, without preferential subscription but allowing such shareholders to subscribe on a pro rata basis. Financing of €2.6 million in this public offer is 100% guaranteed by a group of TME Pharma shareholders and a corporate partner, who will take up any remaining shares not subscribed by existing shareholders in the priority period.
This guaranteed capital injection extends TME Pharma’s financial visibility from January 2025 into June 2025 under its current plans, with the goal of completing ongoing initiatives with regards to licensing, financing, spin-out or a strategic transaction for both of the company’s compounds, NOX-A12 and NOX-E36, during this timeframe. Should additional time be required beyond June 2025 to reach these goals, TME Pharma will operate under a significantly reduced operational cost base transitioning to a virtual structure.
Key Details of the Public Offer:
- Launch of the public offer: December 12, 2024
- Subscription rate: For each four (4) shares held on the record date (December 11, 2024), shareholders are entitled to purchase five (5) newly issued shares. For any shareholders holding less than four (4) shares, for each share held on the record date, shareholders are entitled to purchase one (1) newly issued share
- Price of newly issued share: €0.05
- Subscription period of the priority period: From December 12 to December 18, 2024 (inclusive)
- Results of the public offer: December 23, 2024
- Issuance date: December 27, 2024
IMPORTANT: Shareholders who wish to participate in the public offer are advised to contact their financial intermediary as soon as possible as they may require action before the end of the priority period on December 18, 2024.
More information related to the Public Offer can be found in the following materials:
Press Releases:
| Date | Title | Download | ||
| 2024, December 23 08:00 a.m. | TME Pharma announces successful completion of Euro 2.6 million public offer with strong shareholder support |  |  | |
| 2024, December 12 08:00 a.m. | TME Pharma announces the launch of fully guaranteed public offer for Euro 2.6 million open only to shareholders to enable completion of strategic transactions by June 2025 | | | |